Monoclonal antibody therapy interleukin-1 targeting

Monoclonal and polyclonal antibodies directed at reactive T cells are important adjunct therapies and provide a unique opportunity to target specifically immune-reactive cells. Finally, newer small molecules and antibodies have expanded the arsenal of immunosuppressives. In particular, mTOR (mammalian target of rapamycin) inhibitors (sirolimus, everolimus) and anti-CD25 (interleukin [IL]-2 receptor) antibodies (basiliximab, daclizumab) target growth factor pathways, substantially limiting clonal expansion and potentially promoting tolerance. 

---